文献速递耳科与耳神经

铂类未暴露患者接受免疫检查点抑制剂后的听力损失发生率

Rate of Hearing Loss in Platinum-Naïve Patients Receiving Immune Checkpoint Inhibitors.
PubMed 文献 · Otolaryngol Head Neck Surg · 2026-03-07

这项回顾性队列研究纳入2017至2022年接受免疫检查点抑制剂(ICI)且无铂类化疗史、有基线与治疗后听力图的29例患者。结果显示20.7%达到CTCAE≥1级听力损失,ASHA与TUNE标准下分别为44.8%和27.6%,听力损失组基线至随访听力图间隔显著更长。

要点

  • 铂类未暴露ICI患者中20.7%出现CTCAE≥1级听力损失。
  • ASHA与TUNE标准下听力损失比例分别为44.8%和27.6%。
  • 听力损失组基线至随访听力图间隔显著更长,需标准化听力学监测。

核心结论

  • 相当比例的铂类未暴露ICI监测患者符合听力损失标准。
  • 需前瞻性研究结合标准化听力学监测以量化ICI耳毒性的真实发生率。

研究设计与样本

  • 回顾性队列研究,三级医疗中心,纳入2017年1月1日至2022年12月31日接受ICI且有基线与治疗后听力图的铂类未暴露患者。
  • 从15390例ICI接受者中筛选出29例符合纳入标准的铂类未暴露患者。

主要发现

  • 29例中6例(20.7%)出现CTCAE 1级或以上听力损失。
  • ASHA标准下听力损失比例为44.8%,TUNE标准下为27.6%。
  • 听力损失组基线至随访听力图间隔显著更长:CTCAE平均差590.3天(P<.01),ASHA 280.9天(P=.05),TUNE 122.1天(P=.46)。
  • 其他被认为混杂因素的协变量与结局无显著关联。

关键数值与推荐

  • 主要结局为按美国国家癌症研究所CTCAE定义的听力变化。
  • 次要结局为按ASHA和TUNE标准定义的听力变化。

临床怎么用

  • 对接受ICI的铂类未暴露患者应考虑标准化听力学监测以识别听力损失。
  • 解读听力损失发生率时需注意基线至随访听力图间隔的影响。

局限性

  • 回顾性设计且样本量仅29例。
  • 听力损失组基线至随访听力图间隔显著更长,可能影响发生率估计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Hearing loss from immune checkpoint inhibitors (ICIs) has been documented in case reports and case series. We present the largest retrospective study investigating the rate of ICI-related ototoxicity in a monitored cohort of platinum-naïve patients. STUDY DESIGN: Retrospective cohort study. SETTING: Tertiary-care center. METHODS: Patients treated with ICI between January 1, 2017, and December 31, 2022, with baseline and post-treatment audiograms, were included. Patients with a history of platinum-based chemotherapy were excluded. Demographics, oncologic diagnosis, ICI treatment details, and temporal bone irradiation (TBRT) were recorded. Audiometric thresholds were compared before and after ICI therapy. The primary outcome measure was a change in hearing as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE). Secondary outcome measures included changes in hearing using the American Speech-Language-Hearing Association (ASHA) and TUNE criteria. RESULTS: Among 15,390 ICI recipients, 29 platinum-naïve patients met the inclusion criteria. Six of 29 patients (20.7%) experienced a CTCAE grade 1 or higher hearing loss. The proportions of hearing loss as defined by ASHA and TUNE criteria were 44.8% and 27.6%, respectively. The length of time between baseline and follow-up audiograms was significantly longer among patients with hearing loss (mean difference [days]: CTCAE: 590.3, P < .01; ASHA: 280.9, P = .05; and TUNE: 122.1, P = .46). No other potential covariates believed to be confounders were significantly associated with the outcome. CONCLUSION: A significant proportion of our monitored platinum-naïve ICI patients met hearing-loss criteria. Prospective studies with standardized audiologic surveillance are needed to further quantify the true incidence of ICI ototoxicity.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Brooks KA, Gidley CG, Grimley O, et al. Rate of Hearing Loss in Platinum-Naïve Patients Receiving Immune Checkpoint Inhibitors. Otolaryngol Head Neck Surg. 2026. PMID: 41793286. doi:10.1002/ohn.70191

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。